May 12
|
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
|
May 9
|
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
|
May 8
|
Q1 2025 Vir Biotechnology Inc Earnings Call
|
May 8
|
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
|
May 7
|
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
|
May 7
|
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
|
Apr 9
|
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple
|
Mar 13
|
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
|
Mar 1
|
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
|
Feb 27
|
Q4 2024 Vir Biotechnology Inc Earnings Call
|
Feb 27
|
Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
Feb 26
|
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
|
Feb 26
|
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
|
Feb 19
|
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
|
Feb 12
|
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
|
Jan 10
|
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
|
Jan 9
|
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
|
Jan 9
|
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
|
Jan 8
|
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment
|
Jan 8
|
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
|